These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 30793928)

  • 1. Effect of acarbose on cardiovascular events and new-onset diabetes in patients with coronary heart disease and impaired glucose tolerance.
    Wei Y; Xu W
    Future Cardiol; 2019 Mar; 15(2):127-133. PubMed ID: 30793928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
    Holman RR; Coleman RL; Chan JCN; Chiasson JL; Feng H; Ge J; Gerstein HC; Gray R; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Sun Y; Theodorakis MJ; Tendera M; Tucker L; Tuomilehto J; Wei Y; Yang W; Wang D; Hu D; Pan C;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):877-886. PubMed ID: 28917545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
    Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
    Diabetes Res Clin Pract; 2020 Dec; 170():108488. PubMed ID: 33035598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial.
    Holman RR; Bethel MA; Chan JC; Chiasson JL; Doran Z; Ge J; Gerstein H; Huo Y; McMurray JJ; Ryden L; Liyanage W; Schröder S; Tendera M; Theodorakis MJ; Tuomilehto J; Yang W; Hu D; Pan C;
    Am Heart J; 2014 Jul; 168(1):23-9.e2. PubMed ID: 24952856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial.
    Gerstein HC; Coleman RL; Scott CAB; Xu S; Tuomilehto J; Rydén L; Holman RR;
    Diabetes Care; 2020 Sep; 43(9):2242-2247. PubMed ID: 32641379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    JAMA; 2003 Jul; 290(4):486-94. PubMed ID: 12876091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.
    Van de Laar FA; Lucassen PL; Akkermans RP; Van de Lisdonk EH; De Grauw WJ
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005061. PubMed ID: 17054235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular benefits of acarbose in impaired glucose tolerance and type 2 diabetes.
    Zeymer U
    Int J Cardiol; 2006 Feb; 107(1):11-20. PubMed ID: 16337493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What does the Acarbose Cardiovascular Evaluation (ACE) trial tell us?
    Holman RR
    J Diabetes; 2018 Aug; 10(8):683-685. PubMed ID: 29774661
    [No Abstract]   [Full Text] [Related]  

  • 10. Acarbose in the prevention of cardiovascular disease in subjects with impaired glucose tolerance and type 2 diabetes mellitus.
    Delorme S; Chiasson JL
    Curr Opin Pharmacol; 2005 Apr; 5(2):184-9. PubMed ID: 15780829
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular Benefits of Acarbose vs Sulfonylureas in Patients With Type 2 Diabetes Treated With Metformin.
    Hsu PF; Sung SH; Cheng HM; Shin SJ; Lin KD; Chong K; Yen FS; Yu BH; Huang CT; Hsu CC
    J Clin Endocrinol Metab; 2018 Oct; 103(10):3611-3619. PubMed ID: 30113697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data.
    Chiasson JL; Josse RG; Gomis R; Hanefeld M; Karasik A; Laakso M;
    Diabetologia; 2004 Jun; 47(6):969-75; discussion 976-7. PubMed ID: 15164169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Who should benefit from the use of alpha-glucosidase inhibitors?
    Godbout A; Chiasson JL
    Curr Diab Rep; 2007 Oct; 7(5):333-9. PubMed ID: 18173965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Acarbose on Long-Term Prognosis in Acute Coronary Syndromes Patients with Newly Diagnosed Impaired Glucose Tolerance.
    Yun P; Du AM; Chen XJ; Liu JC; Xiao H
    J Diabetes Res; 2016; 2016():1602083. PubMed ID: 26770983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acarbose for the prevention of diabetes, hypertension, and cardiovascular disease in subjects with impaired glucose tolerance: the Study to Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM) Trial.
    Chiasson JL
    Endocr Pract; 2006; 12 Suppl 1():25-30. PubMed ID: 16627376
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review.
    Joshi SR; Standl E; Tong N; Shah P; Kalra S; Rathod R
    Expert Opin Pharmacother; 2015; 16(13):1959-81. PubMed ID: 26255950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation.
    Rudovich NN; Weickert MO; Pivovarova O; Bernigau W; Pfeiffer AF
    Diabetes Technol Ther; 2011 Jun; 13(6):615-23. PubMed ID: 21488802
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of medical resources and costs among patients with coronary heart disease and impaired glucose tolerance in the Acarbose Cardiovascular Evaluation trial.
    Morrow LM; Becker F; Coleman RL; Gerstein HC; Rydén L; Schöder S; Gray AM; Leal J; Holman RR;
    J Diabetes; 2024 Feb; 16(2):e13473. PubMed ID: 37915263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline characteristics and temporal differences in Acarbose Cardiovascular Evaluation (ACE) trial participants.
    Theodorakis MJ; Coleman RL; Feng H; Chan J; Chiasson JL; Ge J; Gerstein HC; Huo Y; Lang Z; McMurray JJ; Rydén L; Schröder S; Tendera M; Tuomilehto J; Yang W; Hu D; Pan C; Holman RR;
    Am Heart J; 2018 May; 199():170-175. PubMed ID: 29754657
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.